Denali Capital Acquisition in a proxy filing called a Jan. 4 meeting for shareholders to vote on its proposed combination with Longevity Biomedical, which is focused on advancing new technologies across therapeutics, health monitoring and digital health solutions “to increase human health span.”
As announced in January, the deal has a pro forma equity valuation of approximately $236.2 million, which assumes zero redemptions.
Longevity in August agreed to waive the deal’s $30 million cash closing condition.
The SPAC has secured an $18 million PIPE commitment from FutureTech Capital to support the acquisition. Read more.
